MétaCan
Menu
Back to cohort
Record W4416415050 · doi:10.1093/ofid/ofaf653

First-Line Switch to B/F/TAF for Treatment of HIV in Older Adults ≥60 Years in Kenya (the B/F/TAF-Elderly Study)

2025· article· en· W4416415050 on OpenAlexaff
Loice Achieng Ombajo, Jeremy Penner, Joseph Nkuranga, Victor Omodi, Edwin Otieno, Jared Mecha, Simon Wahome, Florentius Ndinya, Rukia Aksam, Sanjay Bhagani, Rose Wafula, Anton Pozniak, Diana Nyakoe, Ruth Wanjohi, Arnold N. Onyango, Foram Rajnkant Bhogayata, Susan Onywera, Martha Atandi, Agatha Theuri, Elizabeth Kamau, Susan Wanjiru, Eunice Karuoya, Amos Ongubo, Gerald Kiambi, S. Juliet, Lillian Gekonge, Florence Kinyanjui, Betty Chepchumba, Alex Morwabe, Kevin Wauna, Felix Hinga

Bibliographic record

VenueOpen Forum Infectious Diseases · 2025
Typearticle
Languageen
FieldMedicine
TopicHIV-related health complications and treatments
Canadian institutionsUniversity of British Columbia
FundersUniversity of NairobiGilead Sciences
KeywordsHuman immunodeficiency virus (HIV)PopulationAntiretroviral therapyYoung adult

Abstract

fetched live from OpenAlex

Abstract Background Older people living with HIV (PWH) are disproportionately affected by an increasing burden of comorbidities. There are few clinical trials of switching antiretrovirals in this population, particularly in Africa. Methods In this open-label randomized trial, virally suppressed PWH aged ≥60 years were randomized 1:1 to switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or to continue their current antiretroviral regimen (CAR) at two sites in Kenya. Participants had bone mineral density (BMD) measurement at baseline, and at weeks 24 and 48. Calcium and vitamin D supplementation was provided to all participants beginning partway through the study because of high rates of osteoporosis identified at baseline. The primary endpoints were proportion of participants with plasma HIV-1 RNA of ≥50 copies/mL at week 48 using the US Food and Drug Administration snapshot algorithm, a non-inferiority margin of 4%, and the percentage change in the lumbar spine BMD at week 48. We report the primary efficacy, BMD and safety analysis at week 48. The study is continuing to week 96. Results Between March and July 2022, we enrolled 520 participants with 260 randomized to switch to B/F/TAF and 260 to continue CAR and were included in intention-to-treat analysis. At week 48, 1.9% (5/260) of participants had HIV-1 RNA ≥ 50 copies/mL in the B/F/TAF arm and 2.7% (7/260) in the CAR arm (treatment difference [95% CI], −0.8% [−3.4 to 1.8]), indicating non-inferiority. Change in lumbar spine BMD at week 48 was +2.18% in the B/F/TAF arm and 0.68% in the CAR arm (difference 1.51, CI .27–2.76, P .017). Treatment-related grade 3 or 4 adverse events were similar across arms (16.9% on B/F/TAF; 14.2% on CAR). Fifteen participants had grade 3 or 4 AEs leading to study drug discontinuation, all in the CAR arm due to declining kidney function. More participants on B/F/TAF developed incident dyslipidemia compared with participants on CAR (23% on B/F/TAF; 14% on CAR; P .015). Conclusions Switch to B/F/TAF was non-inferior to CAR and safe in an African population aged ≥60 years.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.045
Threshold uncertainty score0.599

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.336
Teacher spread0.322 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueOpen Forum Infectious DiseasesSame topicHIV-related health complications and treatmentsFrench-language works237,207